Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült KirályságFázis nélkül

Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis

A legfontosabb adatok

Ki végzi
NHS Greater Glasgow and Clyde
Hol
Birmingham, Coventry, Glasgow és Newcastle upon Tyne (Egyesült Királyság)Mind a 4 helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
45 fő, tervezett
Kezdés
2026. márc. 9.
Várható befejezés
2030. máj.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Ixekizumab
  • Tirzepatide
A regiszteradat frissítve
2026. május 4.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan felnőtteket keres, akiknek aktív psoriasisos ízületi gyulladásuk van, és túlsúlyosak vagy elhízottak. Tirzepatidot, ixekizumabot vagy mindkettőt kapnak, és ízületi, zsír- és bőrmintavételen esnek át.

Életkor
18–75 év
Nem
Mindkét nemű jelentkező csatlakozhat
A betegség stádiuma
Legalább 6 hónapja diagnosztizált psoriasisos ízületi gyulladás, amely megfelel a CASPAR-kritériumoknak (legalább 3 pont). Aktív betegség: legalább 3 duzzadt és 3 érzékeny ízület. BMI legalább 27 kg/m^2.
Korábbi kezelés
Nem csatlakozhat, aki korábban kapott tirzepatidot, bármilyen GLP-1 receptor agonistát, ixekizumabot, rituximabot vagy inzulint (a rövid ideig tartó használat megengedett). Nem lehet több mint 3 fejlett terápiás osztály sikertelen kipróbálása. Nem kaphatott szekukinumabot és bimekizumabot is.

A részvétel fő kizáró okai

  • 1-es típusú cukorbetegség vagy inzulinnal kezelt 2-es típusú cukorbetegség
  • Jelenlegi HIV-, hepatitis B- vagy hepatitis C-fertőzés, illetve aktív fertőzés
  • Terhesség, szoptatás vagy tervezett terhesség
  • Hasnyálmirigy-gyulladás, gyulladásos bélbetegség vagy medulláris pajzsmirigyrák a kórtörténetben
  • Véralvadásgátló, amely a mintavételhez nem függeszthető fel biztonságosan

A regiszter feltételei, szó szerint

Mind a 55 feltétel megnézéseKevesebb

Ki vehet részt

  • Age >= 18 years and <=75 years
  • Have a documented diagnosis of PsA for at least 6 months AND fulfil the CASPAR criteria (Defined as >=3 points)
  • Have active PsA defined as >=3 swollen and >=3 tender joints (dactylitis counts as a swollen joint)
  • Have a BMI >= 27 kg/m\^2
  • Have at least one affected joint amenable to ultrasound-guided synovial biopsy (and must undergo successful synovial biopsy prior to randomisation)
  • Have at least one psoriatic plaque amenable to biopsy (up to a maximum of 5 participants per treatment arm can be recruited without skin biopsy if no suitable lesion
  • Capable of giving signed informed consent
  • Willing and able to participate in the study and undergo synovial, adipose and skin (if appropriate) biopsies (under local anaesthetic) on at least 2 occasions

Ki nem vehet részt

  • Prior/Concomitant Therapy:
  • Previous treatment with tirzepatide or any GLP-1 receptor agonist
  • Previous treatment with Ixekizumab
  • Previous treatment with BOTH secukinumab AND Bimekizumab. [note: Previous treatment with one of EITHER secukinumab OR Bimekizumab for PsA/psoriasis is allowed PROVIDED: i) Last dose was >6months before baseline AND ii) Therapy was not stopped due to an IL-17-related side effect OR due to complete primary lack of response
  • Previous treatment with rituximab
  • Failed >3 classes of advanced therapies (regardless of given for PsA or psoriasis), including but not limited to:; TNF inhibitors (adalimumab, etanercept, certolizumab, golimumab, and infliximab); IL-12/23 inhibitors (ustekinumab); IL-23 inhibitors (guselkumab and risankizumab); IL-17 Inhibitors (secukinumab or bimekizumab); Selective co-stimulation modulators (abatacept); Janus Kinase or tyrosine kinase 2 inhibitors (tofacitinib, upadacitinib and deucravacitinib) Note: Prior exposure to phosphodiesterase-4 inhibitors, such as apremilast and conventional synthetic DMARDs, such as methotrexate, are not considered as advanced therapies
  • If currently receiving conventional DMARDs, or apremilast, must have been treated for at least 12 weeks prior to first biopsy visit and on a stable dose for at least 8 weeks prior to first biopsy visit
  • Use or oral, intra-articular, IM or IV corticosteroids 4 weeks prior to first biopsy visit or anticipated/planned prior to the week 12 biopsy visit
  • Topical steroids within 2 weeks of first biopsy visit (participants on topical corticosteroids at baseline willing to leave these off 2 weeks prior to biopsy will be eligible)
  • Live, attenuated or recombinant vaccination within 1 month prior to screening visit or planned before the 12 week visit
  • Antiplatelet or anticoagulant therapy that cannot be safely interrupted:; Clopidogrel or other antiplatelet therapies (note: aspirin is not an exclusion); Vitamin K antagonists (including but not limited to warfarin); Direct inhibitors of thrombin (e.g. dabigatran); Factor Xa inhibitors (e.g. rivaroxaban, apixaban); Heparins (including low-molecular weight heparins (LMWH)
  • Previous treatment with insulin (exception: Use of insulin for gestational diabetes or short-term use (less than 14 days) for acute conditions, such as acute illness, hospitalisation or elective surgery); Medical Conditions:
  • History of severe hypoglycaemia and/or hypoglycaemia unawareness within the 6 months prior to screening
  • Have a self-reported change in body weight greater than 5% (gain or loss) within 3 months prior to screening
  • Prior or planned surgical treatment for obesity, such as gastric bypass (bariatric) surgery or restrictive bariatric surgery (excluding liposuction or abdominoplasty if performed more than 1 year prior to screening)
  • Known clinically significant gastric emptying abnormality (for example, severe gastroparesis or gastric outlet obstruction); or chronically take drugs that directly effect gastroparesis
  • Have had any of the following types of infection within 3 months prior to screening or develops any of the following infections before the baseline visit:; Serious (requiring hospitalisation, or intravenous or equivalent oral antibiotic treatment, or both); Opportunistic. Note: Herpes Zoster is considered active and ongoing until all vesicles are dry and crusted over); Chronic (duration of symptoms, signs and/or treatment of 6 weeks or longer); recurring (including, but not limited to, herpes simplex, herpes zoster, recurring cellulitis, and chronic osteomyelitis)
  • Have evidence or suspicion of active or latent TB (unless screened previously, all will be evaluated for TB prior to initiating treatment) or had latent TB infection that has not been treated with a complete course of appropriate therapy as per local guidelines, unless such therapy is currently underway
  • Major surgery witing 8 weeks prior to screening or planned within 12 weeks from baseline visit
  • Have participated, within the last 30 days prior to trial entry, in a clinical study involving an investigational study intervention. If the previous investigational study intervention has a long half life, then 5 half lives or 30 days (whichever is longer), should have passed prior to screening
  • Diagnosis of type 1 diabetes or insulin treated type 2 diabetes
  • History of ketoacidosis or hyperosmolar state or coma in the last year
  • Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome type 2
  • History of IBD (Crohn's disease or ulcerative colitis)
  • History of chronic or acute pancreatitis
  • A diagnosis or history of malignant disease within 5 years prior to baseline visit, with the following exceptions:; Basal cell and squamous epithelial carcinomas of the skin that have been resected, with no evidence of metastatic disease for 3 years and 2 years, respectively; cervical carcinoma in situ, with no evidence of recurrence within 3 years
  • History of any other condition (such as known drug, alcohol abuse, or psychiatric disorder) that, in the opinion of the investigator, may preclude the participant from following and completing the study
  • History of significant active or unstable major depressive disorder (MDD), suicidal ideation, or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years; Note: Participants with MDD or generalised anxiety disorder whose disease state is considered stable for the past year and expected to remain stable throughout the course of the study, in the opinion of the investigator, may be considered for inclusion if they are not on excluded medications
  • Active infection at screening
  • Current HIV infection
  • Current infection with hepatitis B virus (HBV) (i.e. positive for HBsAg and/or PCR positive for HBV DNA)
  • Current infection with hepatitis C virus (HCV) (i.e. positive for HCV RNA)
  • History of recurrent or chronic infection which in the opinion of the investigator might place a participant at unacceptable risk for participation in the study
  • Renal Impairment with estimated glomerular filtration rate (GFR) of less than or equal to 30ml/min/1.73m\^2
  • Any other condition that is a contraindication to ixekizumab or tirzepatide; Laboratory results:
  • If type 2 diabetic, laboratory evidence of poorly controlled diabetes, including HbA1c >80mmol/mol (>9.5%)
  • Clinical laboratory test results at screening that are outside the normal reference range for the population and are considered clinically significant, or have any of the following specific abnormalities:; Absolute neutrophil count <1.5 x 10\^3/microlitre; Lymphocyte count <0.80 x 10\^3/microlitre; Platelet count <100 x 10\^3/microlitre; Total WBC count <3.00 x 10\^3/microlitre; Haemoglobin <85 g/L (males) or <80g/L (females); AST or ALT levels >3 x upper limit of local normal range; Serum creatinine levels >2.0omg/dL (equivalent to >176.8 micromol/L Participants who fail screening as a result of a minor blood test abnormality/abnormalities may be re-screened and have the test(s) repeated, within 14 days of the previous blood test, at the investigators discretion. If the tests meet the trial entry criteria on the second occasion, then the participant will be deemed to meet the entry criteria for the trial; In women of child bearing potential(WOCBP):
  • Contraindication to local anaesthetics (lidocaine/similar) used for biopsies
  • Any current or past diagnosis of:; proliferative diabetic retinopathy, or; diabetic maculopathy, or; non-proliferative diabetic retinopathy that requires treatment
  • Are, in the judgement of the investigator, actively suicidal or deemed to be at significant risk for suicide
  • Diagnosis of other inflammatory arthritis, such as rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, gout, or enteropathic arthritis
  • Are Pregnant, breastfeeding or planning to become pregnant during the course of the study
  • Not established, or unwilling to use a method of contraception considered highly effective for the duration of the study and at least 4 weeks after the study if they receive tirzepatide, or 10 weeks if they receive ixekizumab. Tirzepatide may decrease the effectiveness of oral contraceptives, so it is advised that WOCBP using an oral contraceptive should add a barrier method of contraception or switch to a non-oral contraceptive method for the first 4 weeks of treatment, and for 4 weeks after each dose increase; Other exclusions:
  • Are currently enrolled in any other clinical study involving an investigational study intervention or any other type of medical research judged not to be scientifically or medically compatible with this study
  • Unable or unwilling to provide informed consent
  • Are unsuitable for inclusion in the study, in the opinion of the investigator or sponsor, for any reason that may compromise the participant's safety or confound data interpretation
  • Any other contra-indications to biopsies (including anti-coagulants) in the opinion of the investigator

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 75 év között vagy?

Helyszínek itt: Egyesült Királyság

  • University Hospitals Birmingham NHS Foundation TrustBirmingham, Egyesült KirályságContact: Andrew Filer (principal investigator)Toborzás még nem indult
  • University Hospitals Coventry and Warwickshire NHS TrustCoventry, Egyesült KirályságContact: Nicola Gullick (principal investigator)Toborzás még nem indult
  • NHS Greater Glasgow and ClydeGlasgow, Egyesült KirályságContact: Dominic RimmerRésztvevőt keres
  • The Newcastle Upon Tyne Hospitals NHS Foundation TrustNewcastle upon Tyne, Egyesült KirályságContact: Arthur Pratt (principal investigator)Toborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a trial to find out how weight loss (achieved by the use of tirzepatide) or ixekizumab treatment affects the characteristics of skin, joint and fat tissues in patients with Psoriatic Arthritis, Psoriasis and obesity/overweight BMI >=27.

A teljes eredeti leírásKevesebb

Participants will be allocated either Tirzepatide, Ixekizumab or both. Samples of joint tissue, fat and skin will be taken at the start of the study and week 12. Blood and urine samples will also be taken.

The primary objective will be to assess the changes seen in the joint, fat and skin tissue samples 12 weeks after starting the medications (additional analysis will be done on the optional 36 week samples).

Secondary objectives will be

* To assess the changes seen in blood 4, 12, 36 and 52 weeks after starting the medication. * To compare the changes seen in tissue and blood between Ixekizumab and Tirzepatide/Weight loss. * To see how the changes seen in the tissue relate to weight loss.

A vizsgálat 3 csoportja

  • Tirzepatide groupMár használt kezelés, összehasonlításként

    Kezelés: Tirzepatide

  • Ixekizumab groupMár használt kezelés, összehasonlításként

    Kezelés: Ixekizumab

  • Combined tirzepatide and ixekizumabMár használt kezelés, összehasonlításként

    Kezelés: Ixekizumab és Tirzepatide

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
Illeszkedési kérdések
Forrás: NCT07443956: ki vehet részt
A regiszteradat frissítve
2026. május 4.